Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Al Janabi, Omar ^a   Taubert, Helge ^a   Lohse Fischer, Andrea ^b   Fröhner, Michael ^b   Wach, Sven ^a   Stöhr, Robert ^a   Keck, Bastian ^a   Burger, Max ^c   Wieland, Wolf ^d   Erdmann, Kati ^b   Wirth, Manfred P ^b   Wullich, Bernd ^a   Baretton, Gustavo ^b   Magdolen, Viktor ^e   Kotzsch, Matthias ^b   Füssel, Susanne ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d CARITAS KRANKENHAUS ST JOSEF   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR; RNA; SERPINE1 PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RISK FACTOR; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; SURVIVAL RATE;

AGED; ANTIGENS, NEOPLASM; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84901330448     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/972587     Document Type: Article

References (42)

1. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D. M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010 127 12 2893 2917 2-s2.0-78049485263 10.1002/ijc.25516
2. Miyake H., Fujisawa M., Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches. International Journal of Urology 2013 20 3 301 311
3. Truong M., Yang B., Jarrard D. F., Toward the detection of prostate cancer in urine: a critical analysis. Journal of Urology 2013 189 2 422 429
4. Mondino A., Blasi F., uPA and uPAR in fibrinolysis, immunity and pathology. Trends in Immunology 2004 25 8 450 455 2-s2.0-3242699717 10.1016/j.it.2004.06.004 (Pubitemid 38951087)
5. McMahon B., Kwaan H. C., The plasminogen activator system and cancer. Pathophysiology of Haemostasis and Thrombosis 2008 36 3-4 184 194 2-s2.0-61449244797 10.1159/000175156
6. Duffy M. J., McGowan P. M., Gallagher W. M., Cancer invasion and metastasis: changing views. Journal of Pathology 2008 214 3 283 293 2-s2.0-38949143636 10.1002/path.2282 (Pubitemid 351212383)
7. Mengele K., Napieralski R., Magdolen V., Reuning U., Gkazepis A., Sweep F., Brünner N., Foekens J., Harbeck N., Schmitt M., Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert review of molecular diagnostics 2010 10 7 947 962 2-s2.0-78649269236
8. Duffy M. J., The urokinase plasminogen activator system: role in malignancy. Current Pharmaceutical Design 2004 10 1 39 49 2-s2.0-0347917028 10.2174/1381612043453559 (Pubitemid 38072742)
9. Dass K., Ahmad A., Azmi A. S., Sarkar S. H., Sarkar F. H., Evolving role of uPA/uPAR system in human cancers. Cancer Treatment Reviews 2008 34 2 122 136 2-s2.0-40649121508 10.1016/j.ctrv.2007.10.005
10. Duffy M. J., Maguire T. M., McDermott E. W., Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. Journal of Surgical Oncology 1999 71 2 130 135 (Pubitemid 29288493)
11. Schmitt M., Harbeck N., Thomssen C., Wilhelm O., Magdolen V., Reuning U., Ulm K., Höfler H., Jänicke F., Graeff H., Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy. Thrombosis and Haemostasis 1997 78 1 285 296 2-s2.0-0030857717 (Pubitemid 27289256)
12. Schmitt M., Mengele K., Napieralski R., Magdolen V., Reuning U., Gkazepis A., Sweep F., Brünner N., Foekens J., Harbeck N., Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Review of Molecular Diagnostics 2010 10 8 1051 1067 2-s2.0-78649277216 10.1586/erm.10.71
13. Cozzi P. J., Wang J., Delprado W., Madigan M. C., Fairy S., Russell P. J., Li Y., Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Human Pathology 2006 37 11 1442 1451 2-s2.0-33750073572 10.1016/j.humpath.2006.05.002 (Pubitemid 44584322)
14. Kumano M., Miyake H., Muramaki M., Furukawa J., Takenaka A., Fujisawa M., Expression of urokinase-type plasminogen activator system in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urologic Oncology 2009 27 2 180 186 2-s2.0-61649122594 10.1016/j.urolonc.2008.01.012
15. Gupta A., Lotan Y., Ashfaq R., Roehrborn C. G., Raj G. V., Aragaki C. C., Montorsi F., Shariat S. F., Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. European Urology 2009 55 5 1124 1133 2-s2.0-62649132399 10.1016/j.eururo.2008. 06.054
16. Riddick A. C., Shukla C. J., Pennington C. J., Bass R., Nuttall R. K., Hogan A., Sethia K. K., Ellis V., Collins A. T., Maitland N. J., Ball R. Y., Edwards D. R., Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. British Journal of Cancer 2005 92 12 2171 2180 2-s2.0-22044445706 10.1038/sj.bjc.6602630 (Pubitemid 40966253)
17. Miyake H., Hara I., Yamanaka K., Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999 39 2 123 129 (Pubitemid 29194284)
18. Shariat S. F., Roehrborn C. G., McConnell J. D., Park S., Alam N., Wheeler T. M., Slawin K. M., Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. Journal of Clinical Oncology 2007 25 4 349 355 2-s2.0-33846978442 10.1200/JCO.2006.05.6853 (Pubitemid 350002982)
19. Shariat S. F., Karam J. A., Walz J., Roehrborn C. G., Montorsi F., Margulis V., Saad F., Slawin K. M., Karakiewicz P. I., Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clinical Cancer Research 2008 14 12 3785 3791 2-s2.0-50849143820 10.1158/1078-0432.CCR-07-4969
20. Almasi C. E., Brasso K., Iversen P., Pappot H., Høyer-Hansen G., Danø K., Christensen I. J., Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate 2011 71 8 899 907 2-s2.0-79953687971 10.1002/pros.21306
21. Pilronen T., Haese A., Huland H., Steuber T., Christensen I. J., Brünner N., Danø K., Høyer-Hansen G., Lilja H., Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clinical Chemistry 2006 52 5 838 844 2-s2.0-33646336629 10.1373/clinchem.2005.064253 (Pubitemid 43673262)
22. Luther T., Kotzsch M., Meye A., Langerholc T., Füssel S., Olbricht N., Albrecht S., Ockert D., Muehlenweg B., Friedrich K., Grosser M., Schmitt M., Baretton G., Magdolen V., Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer. Thrombosis and Haemostasis 2003 89 4 705 717 2-s2.0-0037391933 (Pubitemid 36456968)
23. Biermann J. C., Holzscheiter L., Kotzsch M., Luther T., Kiechle-Bahat M., Sweep F. C. G. J., Span P. N., Schmitt M., Magdolen V., Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. International Journal of Molecular Medicine 2008 21 2 251 259 2-s2.0-38949107640 (Pubitemid 351222860)
24. Kotzsch M., Magdolen V., Greither T., Kappler M., Bache M., Lautenschläger C., Füssel S., Eckert A. W., Luther T., Baretton G., Würl P., Taubert H., Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients. BMC Cancer 2011 11, article 273 2-s2.0-79959457472 10.1186/1471-2407-11-273
25. Usher P. A., Thomsen O. F., Iversen P., Johnsen M., Brünner N., Høyer-Hansen G., Andreasen P., Danø K., Nielsen B. S., Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. International Journal of Cancer 2005 113 6 870 880 2-s2.0-11844272703 10.1002/ijc.20665 (Pubitemid 40096866)
26. Gavrilov D., Kenzior O., Evans M., Calaluce R., Folk W. R., Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. European Journal of Cancer 2001 37 8 1033 1040 2-s2.0-0035042671 10.1016/S0959-8049(01) 00077-6 (Pubitemid 32397690)
27. Spyratos F., Bouchet C., Tozlu S., Labroquere M., Vignaud S., Becette V., Lidereau R., Bieche I., Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. Anticancer Research 2002 22 5 2997 3003 2-s2.0-0036766003 (Pubitemid 36069349)
28. Urban P., Vuaroqueaux V., Labuhn M., Delorenzi M., Wirapati P., Wight E., Senn H.-J., Benz C., Eppenberger U., Eppenberger-Castori S., Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. Journal of Clinical Oncology 2006 24 26 4245 4253 2-s2.0-33748988736 10.1200/JCO.2005.05.1912 (Pubitemid 46630781)
29. Castelló R., Landete J. M., España F., Vázquez C., Fuster C., Almenar S. M., Ramón L. A., Radtke K.-P., Estellés A., Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Thrombosis Research 2007 120 5 753 762 2-s2.0-34547948179 10.1016/j.thromres.2006.12.016 (Pubitemid 47268042)
30. Xue A., Scarlett C. J., Jackson C. J., Allen B. J., Smith R. C., Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008 36 2 160 167 2-s2.0-45549094584 10.1097/MPA.0b013e31815750f0
31. Semenza G. L., Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 2003 3 10 721 732 2-s2.0-0142166332 (Pubitemid 37328811)
32. Montgomery N., Hill A., McFarlane S., CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity. Breast Cancer Research 2012 14 3, article R84 10.1186/bcr3199
33. Warnecke-Eberz U., Prenzel K. L., Baldus S. E., Metzger R., Dienes H. P., Bollschweiler E., Hoelscher A. H., Schneider P. M., Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer. Pancreas 2008 36 2 173 177 2-s2.0-45549085544 10.1097/MPA.0b013e31815ac538
34. Sternlicht M. D., Dunning A. M., Moore D. H., Pharoah P. D. P., Ginzinger D. G., Chin K., Gray J. W., Waldman F. M., Ponder B. A. J., Werb Z., Prognostic value of PAI1 in invasive breast cancer: Evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiology Biomarkers and Prevention 2006 15 11 2107 2114 2-s2.0-33845330925 10.1158/1055-9965.EPI-06-0351 (Pubitemid 44877033)
35. Leissner P., Verjat T., Bachelot T., Paye M., Krause A., Puisieux A., Mougin B., Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer 2006 6, article 216 2-s2.0-33748873891 10.1186/1471-2407-6-216 (Pubitemid 44420306)
36. Kotzsch M., Sieuwerts A. M., Grosser M., Meye A., Fuessel S., Meijer-Van Gelder M. E., Smid M., Schmitt M., Baretton G., Luther T., Magdolen V., Foekens J. A., Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: Identification of rab31 as an independent prognostic factor. Breast Cancer Research and Treatment 2008 111 2 229 240 2-s2.0-48149112465 10.1007/s10549-007-9782-6
37. Witzel I. D., Milde-Langosch K., Wirtz R. M., Roth C., Ihnen M., Mahner S., Zu Eulenburg C., Jänicke F., Müller V., Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome. Journal of Cancer Research and Clinical Oncology 2010 136 11 1709 1718 2-s2.0-77957594028 10.1007/s00432-010-0829-4
38. Sakakibara T., Hibi K., Koike M., Fujiwara M., Kodera Y., Ito K., Nakao A., Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer. Cancer Science 2006 97 5 395 399 2-s2.0-33645554623 10.1111/j.1349-7006.2006.00185.x
39. Sakakibara T., Hibi K., Koike M., Fujiwara M., Kodera Y., Ito K., Nakao A., Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. British Journal of Cancer 2005 93 7 799 803 2-s2.0-27144449936 10.1038/sj.bjc.6602743 (Pubitemid 41486440)
40. Zhang L., Zhao Z.-S., Ru G.-Q., Ma J., Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World Journal of Gastroenterology 2006 12 25 3970 3976 2-s2.0-33746238306 (Pubitemid 44097102)
41. Høyer-Hansen G., Lund I. K., Urokinase receptor variants in tissue and body fluids. Advances in Clinical Chemistry 2007 44 65 102 2-s2.0-34347265543 10.1016/S0065-2423(07)44003-3
42. Taubert H., Würl P., Greither T., Kappler M., Bache M., Lautenschläger C., Füssel S., Meye A., Eckert A. W., Holzhausen H.-J., Magdolen V., Kotzsch M., Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. British Journal of Cancer 2010 102 4 731 737 2-s2.0-76949087024 10.1038/sj.bjc.6605520